,

Why Use the Oncotype DX Genomic Prostate Score Test?

The Oncotype DX GPS test gives you and your doctor more information for treatment conversations and decisions.

If you have been diagnosed with localized prostate cancer, discussing management options with your doctor is typically the next step.1-7 The Oncotype DX GPS test gives you and your doctor more information for treatment conversations and decisions.

Oncotype DX GPS test is a genomic test, meaning that it measures the expression of certain genes in prostate cancer cells.4 The results are reported as a Genomic Prostate Score (GPS) result, which can help you and your doctor make decisions about a management plan that's best for you.1

Informing Your Treatment Decision

Your Oncotype DX Genomic Prostate Score Result May Help You Navigate Through Your Treatment Options

Your Oncotype DX Genomic Prostate Score result will arm you with information that may help you take charge of your cancer treatment decision with confidence.

How the test can help you

Surveillance Surgery Radiation
Tumor Analysis

The Oncotype DX GPS test measures the activity (also referred to as expression) of 12 cancer-related genes plus 5 reference genes responsible for the growth and survival of tumor cells.4

  • Provides information that can help clarify how the tumor may act and whether it is likely to be aggressive (adverse pathology).4,5
  • Predicts whether you are likely to die from your cancer or have it spread to other parts of your body (metastasis) within 10 years of surgery.3,6
In addition to your clinical factors, the Oncotype DX GPS test will provide information for you and your doctor to discuss next steps.

Why your tumor's gene activity matters

Not all prostate cancers are the same. However, many are lower risk and can be managed with regular doctor visits delaying or completely avoiding treatments like surgery or radiation.2

It’s important for you to understand your personal risk before deciding on a management plan—with this information in hand you can make a decision that may be better suited to helping you live as long and healthy a life as possible.

Informing active surveillance and immediate treatment decisions

The Oncotype DX GPS test may help you and your health care team understand your individualized risk to inform decisions about what happens next—active surveillance or treatment. In combining your clinical features and your GPS test results, you and your doctor will decide a personalized treatment path that is best for you.

Active surveillance is a treatment plan that can be used for patients whose tumor is not likely to be aggressive. It involves regular check-ups and ongoing testing.1

When to have the test

If you have been recently diagnosed with clinically low-, intermediate-, and high-risk prostate cancer or have yet to decide on a management option, your biopsy tissue may be used to provide additional information about the aggressiveness of your tumor, which may help you choose the right treatment plan.1-7

What’s needed to perform the test

The Oncotype DX GPS test uses a tissue sample from a biopsy performed within the last three years. So, if you’ve had a recent biopsy, no additional procedure is needed.

The test can predict the aggressiveness and biology of the prostate cancer without additional tests or having to remove the tumor by analyzing a very small sample of the tumor tissue.4

REFERENCES

  1. Badani et al. Urol Pract. 2015.
  2. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. V.2.2021.
  3. Van Den Eeden et al. Eur Urol. 2017.
  4. Klein et al. Eur Urol. 2014.
  5. Cullen et al. Eur Urol. 2015.
  6. Cullen et al. Eur Urol. 2020.
  7. Data on file.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed June 1, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.

Making cancer care smarter.™